Fusion Pharmaceuticals Inc. (FUSN): Price and Financial Metrics
GET POWR RATINGS... FREE!
FUSN Stock Price Chart Interactive Chart >
FUSN Price/Volume Stats
|Current price||$8.15||52-week high||$19.00|
|Prev. close||$8.61||52-week low||$6.61|
|Day high||$8.78||Avg. volume||44,232|
|50-day MA||$8.70||Dividend yield||N/A|
|200-day MA||$11.32||Market Cap||346.02M|
Fusion Pharmaceuticals Inc. (FUSN) Company Bio
Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant and is headquartered in Hamilton, Canada.
FUSN Latest News Stream
|Loading, please wait...|
FUSN Latest Social Stream
View Full FUSN Social Stream
Latest FUSN News From Around the Web
Below are the latest news stories about Fusion Pharmaceuticals Inc that investors may wish to consider to help them evaluate FUSN as an investment opportunity.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), today announced the appointment of Isabelle Dussault, Ph.D. as senior vice president, research.
Fusion Pharmaceuticals (FUSN) has teamed up with McMaster University to set up a radiopharmaceutical manufacturing facility in Hamilton. The arrangement involves a 15-year lease agreement with the university. The university will be responsible for building the facility while Fusion will take care of equipping and validating it. The parties are working on getting the plant operating by early 2024. The facility will offer 27,000 square feet of space and be current Good Manufacturing Practice (GMP) compliant. "We will continue to prioritize manufacturing and supply chain infrastructure in our long-term plans, and this facility is an important milestone in executing those plans,” commented Fusion CEO John Valliant.
McMaster University and Fusion Pharmaceuticals say they are working together to build a radiopharmaceutical manufacturing facility in west Hamilton.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it entered a 15-year lease agreement with Hamilton, Ontario-based McMaster University to build a 27,000 square foot current Good Manufacturing Practice (GMP
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 11:00am EDT.
FUSN Price Returns